Exhibit 10.2









Exhibit 10.2




CHAMPIONS BIOTECHNOLOGY, INC.




October 25, 2010



Ronnie Morris, M.D.




Dear Dr. Morris:




We are pleased to offer you the position of President of Champions Biotechnology, Inc. (the
“Company”). You will be employed by, and also serve as President of, the subsidiary of the Company
that is currently being formed in Israel. For so long as you serve as an executive officer of the
Company, the Company will nominate you as a member of the board of directors of the Company. This
offer is contingent upon your signing our Business Protection Agreement, a copy of which is
attached hereto, which protects the Company’s intellectual property and good will, among other
things. You will be entitled to indemnification by the Company to the fullest extent permitted by
law pursuant to the Indemnification Agreement attached hereto.




You will be entitled to salary equal to the minimum wage in Israel, as may be in effect from time
to time, which is currently NIS 3,850 per month. You will not be entitled to receive severance
payments or to receive employee benefits, except as required by applicable Israeli labor law. You
will be entitled to receive options to purchase 5,000,000 shares of common stock of the Company at
the times and on the terms set forth in Schedule A attached hereto.




Upon the closing of the next round of financing of the Company in the aggregate amount of at least
$5,000,000, and on the same price and other terms thereof, you will invest in the Company between
$250,000 and $500,000 (the “Personal Investment”).




Our employment relationship will not be for any specified duration and it will be terminable at
will, which means that either you or the Company may terminate it at any time. To facilitate the
Company’s provision of quality service, we expect you to provide at least 30 days’ advance written
notice if you decide to resign. If you decide to resign , you agree to resign also from the board
of directors of the Company and any subsidiary thereof. Any dispute regarding your employment will
be governed solely by the laws of Israel. You and the Company agree that any action arising out
of your employment will be brought in and will be subject to the exclusive jurisdiction and venue
of the competent courts in Israel.




This letter (including Schedule A attached hereto) contains the entire agreement between you and
the Company and supersedes any prior or agreement, understanding or commitment (oral or written) by
or on behalf of the Company, except for the Business Protection Agreement and the Indemnification
Agreement. The terms of your employment may be amended in the future, but only in writing and
signed by both you and by an authorized officer of the Company.
We expect that your engagement with us would start on October 26, 2010, or another mutually
satisfactory date (such start date, the “Commencement Date”). We will form the Israeli subsidiary
that will employ you as soon as practicable and in no event later than November 30, 2010. We will
cause the Israeli subsidiary to adopt a stock option plan in form and substance satisfactory to you
and retain a trustee under Section 102 of the Israeli Tax Ordinance [New Version], 1961 (“Israeli
Section 102”) and file said plan with the Israel Tax Authority as soon as practicable after its
formation and in no event later than November 30, 2010.




We believe you will be a productive member of our team and we hope you will accept our offer. If
you wish to do so, please sign this letter and return it to the Company within 10 days after the
date of this letter. We look forward to your joining our Company.




	 	 	 	 	 
	 	Champions, Biotechnology, Inc.

 	 
	 	By:  	/s/ Mark Schonau, CFO
 	 
	 	 	 	 
	 	 	 	 



	 	 	 	 	 
	Agreed and accepted:

 	 	 
	/s/ Ronnie Morris
 	 	 
	Employee Signature 	 	 
	 	 	 



Date: October 25, 2010



 












 





Schedule A to Agreement with Dr. Ronnie Morris




Option Terms




	 	•	 	Number of Options Shares: 5,000,000, which will be granted to Dr. Ronnie Morris
pursuant to Israeli Section 102 (the “Personal Options”), provided, however, that at the
election of Dr. Morris, up to 1,500,000 of such options will be granted to the R A Morris
Family Foundation (the “Foundation Options”).
	 
	 	•	 	Option Term: 10 years.
	 
	 	•	 	Exercise Price: The market price of the Company’s common stock, which is $0.875 per
share. Cashless exercise shall be permitted at your election starting two years after the
Commencement Date.
	 
	 	•	 	Vesting Schedule:






	 	•	 	2,500,000 options (i.e., half the Personal Options and half the
Foundation Options, if any) (the “Non-contingent Options”) shall vest monthly over
three years, in 36 equal installments, commencing from the Commencement Date.
	 
	 	•	 	2,500,000 options (i.e., half the Personal Options and half the
Foundation Options, if any) (the “Contingent Options”) shall vest monthly over three
years, in 36 equal installments, commencing from the Commencement Date but subject
also to satisfaction of the following conditions during the option term(the
“Conditions”):






	 	5)	 	Closing of one or more financings of the Company in the
aggregate amount of at least $5,000,000 (including your Personal Investment
and that of Joel Ackerman).
	 
	 	6)	 	Bringing in new Company management.
	 
	 	7)	 	Launching of personalized medicine (oncology) business.
	 
	 	8)	 	Commencing implementation of Business Plan.
	 
	 	•	 	Upon satisfaction of all of the Conditions, all Contingent Options that
would have vested had the vesting commenced from the Commencement Date shall
vest immediately. By way of illustration, if the conditions are satisfied
nine months following the Commencement Date, 9/36ths, or 25% of the
Contingent Options, shall vest.
	 
	 	•	 	So long as the Conditions are not satisfied, the Contingent Options shall
not be granted or exercisable; if all of the Conditions are not satisfied
within the three year vesting period, the Contingent Options shall lapse and
terminate.
	 
	 	•	 	At your request from time to time, the Company shall confirm whether any
of the Conditions has been satisfied, as determined in good faith by its
Board of Directors.






	 	•	 	Notwithstanding the foregoing, all options vest and become fully
exercisable upon a “Change of Control” (as defined below) or termination of
employment without “Cause” (as defined below).






	 	•	 	The Non-Contingent Options will expire 90 days following termination for Cause or
voluntary resignation; the Contingent Options will not be affected by such events, except
that vesting shall cease.
	 
	 	•	 	Grant Date: All of the Non-contingent Options and 2,250,000 of the Contingent Options
shall be granted on the 31st day following the filing of the option plan with
the Israel Tax Authority. The balance of 250,000 Contingent Options shall be granted
immediately upon the satisfaction of the Conditions, on the same terms as the
Non-Contingent Options. For the avoidance of doubt, all or a portion of such Contingent
Options will be vested and will become exercisable pursuant to the above terms. The
Company will take or cause to be taken all requisite actions to ensure capital gains
treatment of the Personal Options under Section 102 of the Israeli Income Tax Ordinance,
including establishing an Israeli subsidiary, adopting an Israeli option plan that complies
with said Section 102, filing such plan with the Israel Tax Authority and retaining a
trustee.
	 
	 	•	 	It is understood that at the present time, in view of the Company’s plans for raising
capital, the Company may not have sufficient authorized but unissued shares of common stock
necessary upon the exercise of the Options. The Company will take such action as may be
reasonable and practical, as promptly as practicable and in any event within 90 days of the
Commencement Date, to increase the number of authorized but unissued shares of common stock
to provide for the shares needed to be issued upon the exercise of the Options (the
“Capital Increase”).
	 
	 	•	 	All shares underlying the options will be registered by the Company with the Securities
and Exchange Commission on Form S-8 within 15 days following the effective date of the
Capital Increase.
	 
	 	•	 	Notwithstanding the foregoing, in no event will you be permitted to hold securities
representing more than 9.9% of the Company’s capital stock on an “equal diluted” basis.



 


ii









 











For purposes of this agreement, the following capitalized terms that have the following respective
meanings:




“Cause” shall mean any of the following: (i) willful misconduct in the performance of your material
duties; (ii) participation in any fraud against the Company; (iii) conviction of, or a plea of
“guilty” or “no contest” to, a felony or any crime involving dishonesty; or (iv) intentional damage
to any property of the Company of material value.




“Change of Control” shall mean the occurrence of any of the following:




(a) any “person,” as such term is currently used in Section 13(d) of the Securities Exchange Act of
1934, as amended (the “1934 Act”) (a “person”), other than Dr. David Sidransky, becomes a
“beneficial owner” (as such term is currently used in Rule 13d-3 promulgated under the 1934 Act (a
“Beneficial Owner”) of 30% or more of the Voting Stock (as defined below) of the Company;




(b) the Board of Directors of the Company adopts any plan of liquidation providing for the
distribution of all or substantially all of the Company’s assets;




(c) all or substantially all of the assets or business of the Company are disposed of in any one or
more transactions pursuant to a sale, merger, consolidation or other transaction (unless the
shareholders of the Company immediately prior to such sale, merger, consolidation or other
transaction beneficially own, directly or indirectly, in substantially the same proportion as they
owned the Voting Stock of the Company, more than fifty percent (50%) of the Voting Stock or other
ownership interests of the entity or entities, if any, that succeed to the business of the
Company);




(d) the Company combines with another company and is the surviving corporation but, immediately
after the combination, the shareholders of the Company immediately prior to the combination hold,
directly or indirectly, fifty percent (50%) or less of the Voting Stock of the combined company; or




(e) Continuing Directors cease to constitute at least a majority of the Board of Directors of the
Company.




“Voting Stock” of any entity shall mean the issued and outstanding share capital or other
securities of any class or classes having general voting power under ordinary circumstances, in the
absence of contingencies, to elect the members of the board of directors (or members of a similar
managerial body if such entity has no board of directors) of such entity.




“Continuing Director” means a director who either was a director of the Company on the Commencement
Date or who became a director of the Company subsequent thereto and whose election, or nomination
for election by the Company’s shareholders, was approved by a majority of the Continuing Directors
then on the Board of Directors of the Company.




 


iii